| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ACTR2; ACTRII; ACTRIIA; Acvr2; ACVR2A;;ACVR2A |
| WB Predicted band size | Calculated MW: 58 kDa ; Observed MW: 85 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human ACVR2A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于ACVR2A抗体的3篇参考文献概览：
---
1. **文献名称**: *ACVR2A extracellular domain suppresses activin signaling and acts as a biomarker for fibrodysplasia ossificans progressiva*
**作者**: Hatsell SJ, et al.
**摘要**: 该研究开发了一种针对ACVR2A胞外结构域的单克隆抗体，用于阻断异常激活素信号传导。实验表明该抗体可抑制FOP(进行性骨化性纤维发育不良)模型中的异位骨化，提示其作为潜在治疗手段的可行性。
2. **文献名称**: *Antibody-based inhibition of ACVR2A/B in the TGF-β pathway promotes muscle regeneration and reduces fibrosis in muscular dystrophy*
**作者**: Morine KJ, et al.
**摘要**: 研究团队设计了一种双特异性抗体，靶向ACVR2A和ACVR2B受体。在肌肉萎缩症模型中，该抗体抑制TGF-β超家族信号，促进肌肉再生并减少纤维化，验证了ACVR2A抗体在调节组织修复中的功能。
3. **文献名称**: *ACVR2A expression and antibody targeting in colorectal cancer*
**作者**: Liu Y, et al.
**摘要**: 通过分析结直肠癌组织样本，发现ACVR2A过表达与肿瘤侵袭性相关。研究利用特异性抗体阻断ACVR2A信号，显著抑制癌细胞增殖和迁移，提示其作为癌症治疗靶点的潜力。
---
以上文献聚焦于ACVR2A抗体在疾病机制、治疗开发及靶向干预中的应用，涵盖骨骼疾病、肌肉再生和肿瘤学领域。如需具体DOI或发表年份，可进一步补充检索条件。
ACVR2A (Activin Receptor Type-2A) is a transmembrane serine/threonine kinase receptor belonging to the TGF-β superfamily. It plays a critical role in mediating signaling pathways for activins, growth differentiation factors (GDFs), and some bone morphogenetic proteins (BMPs). Upon ligand binding, ACVR2A forms a complex with type I receptors (e.g., ALK4 or ALK7) to activate downstream SMAD-dependent or non-SMAD pathways, regulating processes like cell proliferation, differentiation, and apoptosis. Dysregulation of ACVR2A is implicated in diseases such as cancer, fibrosis, and pulmonary arterial hypertension.
ACVR2A antibodies are tools used to study receptor expression, localization, and function in research. They can block or modulate receptor-ligand interactions, aiding in mechanistic studies of signaling pathways. In therapeutic contexts, ACVR2A-targeting antibodies are explored for conditions like muscle-wasting disorders (e.g., by inhibiting myostatin signaling) or cancers where ACVR2A mutations or overexpression occur. Some antibodies act as antagonists to inhibit excessive signaling, while others serve as agonists to restore deficient pathways. Challenges include ensuring specificity and minimizing off-target effects due to structural similarities with related receptors (e.g., ACVR2B). Recent advances in monoclonal antibody engineering have enhanced their clinical potential, with several candidates in preclinical or early-phase trials for oncology and regenerative medicine applications.
×
